Comment on 'effects of locally applied water-filtered infrared a irradiation adjunctive to iloprost and carbon dioxide hand baths in patients with systemic sclerosis and severe Raynaud's phenomenon - a randomized controlled trial'.
Clinical characteristics of patients with antisynthetase syndrome and dermatomyositis-type skin involvement: Insights from the Myo-Spain registry.
To characterize the clinical profile of patients with anti-synthetase syndrome (ASyS) presenting with dermatomyositis (DM)-type skin lesions (ASyS-DM-skin) and compare them with patients with ASyS without DM-type skin lesions (ASyS-nonDM-skin) and patients with DM. We performed a cross-sectional stu…
Pharmacological targeting of the TLR8/AP-1 axis ameliorates scleroderma skin inflammation and fibrosis by suppressing monocyte-mediated endothelial injury.
Toll-like receptor 8 (TLR8) is implicated in systemic sclerosis (SSc) pathogenesis, but its precise cellular mechanisms remain elusive. This study elucidates TLR8's role in monocyte-endothelial crosstalk and evaluates the therapeutic potential of targeting the TLR8/AP-1 axis in SSc. TLR expression i…
Characterisation of Systemic Sclerosis in a Jordanian Cohort: Clinical Features, Diagnostic Patterns, and Health-Related Quality of Life.
To describe the clinical and demographic characteristics of systemic sclerosis (SSc) in a Jordanian cohort and assess patients' psychological well-being, quality of life, and functional disability. This cross-sectional study included all consecutive SSc patients seen at a single rheumatology clinic…
Microvascular barrier - Transdermal and Topical drug delivery in Raynaud's Phenomenon.
Raynaud Phenomenon (RP) is a peripheral vascular disease that results in episodes of vasospasm of the microcirculation of hands and feet, which causes ischemia, pain and functional deficiency. Traditional systemic treatments of RP, such as calcium channel blockers and phosphodiesterase type-5 inhibi…
Identifying candidate core domains for clinical trials in systemic sclerosis-associated Raynaud's phenomenon and digital ulcers.
The OMERACT Scleroderma Vascular Disease Working Group sought to identify essential core outcome domains for inclusion in clinical trials focusing on Raynaud's phenomenon (RP) and/or digital ulcers (DUs) related to systemic sclerosis (SSc). Candidate domains identified from previous qualitative work…